Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Expert Opinion on Drug Safety

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/eods.2.3.263.21375PMID 12904105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Entacapone in the management of Parkinson’s disease

  2002cited by this paper
• Effects of entacapone and tolcapone on mitochondrial membrane potential.

  2002cited by this paper
• Treatment of advanced stage patients with Parkinson's disease.

  2002cited by this paper
• Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.

  2002cited by this paper
• Entacapone‐Induced Hepatotoxicity and Hepatic Dysfunction

  2002cited by this paper
• Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects

  2002cited by this paper
• Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)

  2002cited by this paper
• Recent advances in the genetics and pathogenesis of Parkinson disease

  2002cited by this paper
• Twelve‐month safety of entacapone in patients with Parkinson’s disease

  2001cited by this paper
• Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat

  2001cited by this paper
• Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.

  2000cited by this paper
• Comparative Tolerability of the Newer Generation Antiparkinsonian Agents

  2000cited by this paper
• Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease

  2000cited by this paper
• Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.

  2000cited by this paper
• The rise and fall of tolcapone

  1999cited by this paper
• Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone

  1998cited by this paper
• Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients

  1997cited by this paper
• Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.

  1997cited by this paper
• Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations

  1997cited by this paper
• Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.

  1996cited by this paper
• Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

  1994cited by this paper
• Levodopa: Rational and irrational pharmacology

  1994cited by this paper
• Clinical Pharmacokinetics of Anti-Parkinsonian Drugs

  1987cited by this paper
• Dopamine is a monoamine oxidase B substrate in man

  1977cited by this paper
• Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition

  1974cited by this paper

• Voltammetric measurement of catechol-O-methyltransferase inhibitor tolcapone in the pharmaceutical form on the boron-doped diamond electrode

  2023cites this paper
• A randomized trial of the effects of COMT inhibition on subjective response to alcohol: Moderation by baseline COMT activity and mediation of alcohol self-administration.

  2023cites this paper
• Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone

  2022cites this paper
• The generation of HepG2 transmitochondrial cybrids to reveal the role of mitochondrial genotype in idiosyncratic drug-induced liver injury

  2022cites this paper
• Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease

  2020cites this paper
• In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk

  2020influential citation
• The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.

  2017cites this paper
• Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

  2016cites this paper
• A literature-driven method to calculate similarities among diseases

  2015cites this paper
• Metabolic implications and characterization of hepatic extracellular vesicles in drug-induced liver injury

  2015cites this paper
• Habb-e-Asgand, polyherbal Unani formulation, protects liver and antioxidative enzymes against paracetamol induced hepatotoxicity

  2014cites this paper
• Parkinson's disease biomarkers in peripheral blood T lymphocytes: identification through a proteomic approach

  2013cites this paper
• Identification of liver proteins and their roles associated with carbon tetrachloride-induced hepatotoxicity

  2011cites this paper
• Entacapone

  2010cites this paper
• Dual Beneficial Effects of (-)-Epigallocatechin-3-Gallate on Levodopa Methylation and Hippocampal Neurodegeneration: In Vitro and In Vivo Studies

  2010cites this paper
• Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

  2009cites this paper
• Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease

  2008cites this paper
• Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg

  2008cites this paper
• Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology

  2006cites this paper
• Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy

  2005cites this paper
• Drug-induced liver disease in 2003

  2004cites this paper